Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remdesivir - Gilead Sciences

Drug Profile

Remdesivir - Gilead Sciences

Alternative Names: Captisol-enabled remdesivir; Captisol®-enabled GS 5734; GS-5734; Veklury

Latest Information Update: 29 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer China-Japan Friendship Hospital; Gilead Sciences; INSERM; National Institute of Allergy and Infectious Diseases
  • Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Phosphorus compounds; Pyridazines; Pyrroles; Small molecules; Triazines
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections
  • Phase II Ebola virus infections

Most Recent Events

  • 25 Jun 2020 The Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion for conditional marketing authorisation (CMA) of remdesivir for the treatment of COVID-2019 infections
  • 25 Jun 2020 Efficacy data from the phase III trial in COVID-2019 infections released by European Medicines Agency
  • 16 Jun 2020 Gilead Sciences plans the phase II/III CARAVAN trial for COVID-2019 infections (In neonates, In infants, In children, In adolescents) (IV) in June 2020 (NCT04431453)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top